CryoPort Aktie WKN: A14THD ISIN: US2290503075

Börse
Nasdaq

Kurs zur CRYOPORT INC. DL-,01 Aktie

47,21 USD

+1,29 % +0,60 USD

Login

Kursdaten

Geld (Stk.) 47,210 (3.000)
Brief (Stk.) 47,250 (800)
Spread 0,085
Geh. Stück ca. 408 Tsd
Eröffnung 47,170
Vortag 46,610
52 Wochen Hoch 60,760
52 Wochen Tief 13,010

Stand: 20.10.2020 - 02:00:00 Uhr

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker

Community-Beiträge (10)

Neu laden

Alle Kommentare Neu laden

Ayur_Vader
Ayur_Vader vom 30.09.20 16:01 Uhr

https://www.obermatt.com/de/aktien/cryoport-nasdaqcm-cyrx/aktien-analyse.html

Ayur_Vader
Ayur_Vader vom 23.09.20 22:35 Uhr

https://www.nashvillepost.com/business/health-care/article/21143482/cryoport-eyes-important-role-in-covid-vaccine-distribution

Ayur_Vader
Ayur_Vader vom 31.08.20 06:51 Uhr

To date in 2020, Cryoport has: -Implemented Veri-Clean™, the first and only validated cleaning and disinfection process in the life science industry to support Chain of Compliance® as well as the recently published ISO TC276 standards for the transportation of cells for therapeutic use. -Recently launched our new validated C3™ Controlled Room Temperature (15-25ºC) Shipper with near-real time monitoring during shipment. -Finalized steps to open our first Global Supply Chain Centers in Morris Plains, NJ and Houston, TX, which will include both logistics and bioservices early next year. -Signed a multi-year partnership with Japan's leading pharma wholesaler and distributor, expanding our reach in the Asia Pacific region. We remain dedicated to doing all that we can to support the success of our clients – because after all, their success means the improved health of patients around the world. The COVID-19 pandemic makes this mission more important than ever. We continue to proudly support our clients’ crucial work, and we are honored to play a critical role in creating, sustaining, and saving lives.

Ayur_Vader
Ayur_Vader vom 31.08.20 06:49 Uhr

Our Success Is Your Success: Cryoport Marks Milestones While Supporting Clients Through the Pandemic Tue, Aug 11, 2020 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport Cryoport recently marked some significant milestones. We are now supporting four commercial biopharma therapies, and a fifth's commercial submission was recently validated by the European Medicines Agency. The number of active clinical trials Cryoport supports is nearing 500 globally. We are on track to open new locations in the U.S. in early 2021, and soon we will offer biostorage, which is becoming more integral as cell and gene research and commercializations ramp up. These milestones come in the middle of a once-in-a-century, global pandemic that has dramatically changed daily life for billions of people. Our clients are working tirelessly – not only on COVID-19 research for accurate diagnostic testing, treatments and vaccines, but in their continued efforts to address critical and unmet healthcare needs of patients outside of COVID-19. We applaud these organizations for forging through these challenging times to keep progress in healthcare moving forward. In turn, the global team at Cryoport has continued to work diligently to help our life science clients thrive by supporting their research and commercial goals with our array of best in class temperature-controlled solutions.

Ayur_Vader
Ayur_Vader vom 31.08.20 06:45 Uhr

http://ir.cryoport.com/news-releases/2020/02-26-2020-132913683

Ayur_Vader
Ayur_Vader vom 31.08.20 06:42 Uhr

http://ir.cryoport.com/news-releases/2020/08-04-2020-133049633

Ayur_Vader
Ayur_Vader vom 31.08.20 06:42 Uhr

http://ir.cryoport.com/news-releases/2020/08-21-2020-122958189

Ayur_Vader
Ayur_Vader vom 31.08.20 06:41 Uhr

http://ir.cryoport.com/news-releases/2020/08-25-2020-120124308

Ayur_Vader
Ayur_Vader vom 31.08.20 06:40 Uhr

http://otp.investis.com/clients/us/cryoport/SEC/sec-show.aspx?Type=page&FilingId=14322580-27825-153550&CIK=0001124524&Index=11100

Ayur_Vader
Ayur_Vader vom 31.08.20 06:39 Uhr

Ich eröffne mal die Runde! Starkes Unternehmen mit guter Zukunftsperspektive, z.B. Stammzellen-Logistik. Hätte gern einige Aktien, sind aber leider über ING nicht handelbar. Kann mir jemand sagen warum, bzw. wo das geht?

Alle Kommentare Neu laden

Neue Kommentare
1 CRYOPORT INC. DL-,01 Hauptdiskussion

Geld/Brief Kurse

Börse Geld Brief Zeit Volumen Kurs
Nasdaq 47,21 47,25 1603152000 02:00 408.349 47,21 USD
AMEX 0,00 0,00 1603152000 02:00 0 47,77 USD

Realtime / Verzögert

CryoPort

Börsennotierung

Marktkapitalisierung
158,330 Mrd EUR
Anzahl der Aktien
39,46 Mio Stück

Grundlegende Daten zur CRYOPORT INC. DL-,01 Aktie

Finanzdaten 2016 2017 2018 2019 2020 2021
Ergebnis je Aktie (bereinigt) - - - - - -
Cashflow - - - - - -
Eigenkapitalquote - - - - - -
Verschuldungsgrad - - - - - -
Eigenkapitalrendite - - - - - -
Gesamtkapitalrendite - - - - - -
EBITDA - - - - - -
EBIT - - - - - -
Fundamentaldaten 2016 2017 2018 2019 2020 2021
Dividendenrendite - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - -
Dividende je Aktie - - - - - -
Bilanzdaten 2016 2017 2018 2019 2020 2021
Netto-Provisionsüberschuss - - - - - -
Umsatzerlöse - - - - - -
Ergebnis vor Steuern - - - - - -
Steuern - - - - - -
Ausschüttungssumme - - - - - -
Nettoverzinsung - - - - - -
Zinsertrag - - - - - -
Gesamtertrag - - - - - -